BioSpace News Archive

Tessera Therapeutics announced today the appointment of Elliott Sigal, M.D., Ph.D. and Mary Rozenman, Ph.D. to the company’s Board of Directors.

With an estimated 6 million people worldwide living with Parkinson’s, and an estimated 60,000 newly diagnosed annually, resources to help navigate available treatments to manage Parkinson’s care are critical.

NeuroMetrix, Inc. (Nasdaq: NURO) today announced that Quell technology will be used in a double-blinded, randomized, sham-controlled trial to determine whether transcutaneous electrical nerve stimulation (TENS) is an effective, acceptable and feasible method of pain relief in patients with NMOSD.

PDS Biotechnology Corporation, a clinical-stage immunotherapy company developing novel cancer therapies based on the Company’s proprietary Versamune® T-cell activating technology, announced the pricing of its previously announced underwritten public offering of 5,294,118 shares of its common stock at a public offering price of $8.50 per share.

Mezzion Pharma Co., Ltd., and Mezzion Pharmaceuticals, Inc., a leader in the field of rare single ventricle congenital heart disease and SVHD patients with Fontan circulation, is pleased to announce that Bill Breitenbach has joined Mezzion as the Chief Commercial Officer effective June 1st, 2021.

Prometheus Laboratories, Inc. (“Prometheus”), a leader in precision healthcare, announces the execution of an agreement with MultiPlan, a trusted partner to more than 700 healthcare payors.

Linnaeus Therapeutics, Inc. (Linnaeus), a privately held clinical-stage biopharmaceutical company focused on the development and commercialization of novel small molecule oncology therapeutics, today announced the expansion of its ongoing clinical collaboration with Merck to include multiple additional phase 2 cohorts

Moleculin Biotech, Inc., a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors and viruses, announced that as part of the annual reconstitution of the Russell stock indexes, Moleculin has been selected to be added to the Russell 2000® Index effective after the close of the U.S. equity markets on June 25, 2021.

LivaNova PLC today announced it has received approval from the U.S. Food and Drug Administration (FDA) to proceed with its investigational device exemption (IDE) clinical study.

IAVI has received an award of €22.8 million from the European & Developing Countries Clinical Trials Partnership (EDCTP) and the Coalition for Epidemic Preparedness Innovations (CEPI) to conduct a Phase IIb clinical trial of a novel vaccine candidate to prevent Lassa fever disease.